MADISON, Wis., Aug. 24, 2017 — Propeller Health, a leading digital solution for respiratory medicine, today announced the expansion of its 2015 collaboration with GSK, enabling both companies to prepare for and undertake commercial activities using the Propeller clip-on sensor and software platform for use with GSK’s ELLIPTA Inhaler. The companies will continue ongoing research and development efforts to collect evidence from the Propeller clip-on sensor and software platform used in conjunction with GSK’s respiratory medicines for asthma and COPD.
The announcement follows successful CE marking and US FDA 510(k) class II clearance of the Propeller sensor and software program for the ELLIPTA Inhaler, in late 2016. The clip-on sensor for the ELLIPTA Inhaler automatically records medication use, which the Propeller platform analyzes and presents to patients and physicians through its data-driven digital interfaces, providing an in-depth view into adherence.
“We are excited to be working closely with GSK to make the sensor for the ELLIPTA inhaler available in our commercial programs, and for the first time, as part of commercial pilots with GSK outside the US,” said David Van Sickle, CEO and co-founder of Propeller. “Companion digital experiences simplify and personalize the management of chronic respiratory disease, and help ensure individuals and their physicians realize the benefits of inhaled medicines.”
Eric Dube, Senior Vice President and Head, Global Respiratory Franchise GSK, said: “Digital innovations, like sensor technologies, will help us ensure patients receive the best possible package of care management and treatment for their respiratory condition. We are excited to expand our collaboration with Propeller as a further step in our journey towards achieving connected health systems for people with asthma and COPD.”
The Propeller platform has been used by patients and physicians in over 55 commercial programs across the United States, including major healthcare systems, payers, employers and other commercial partners. It is compatible with the majority of commonly used asthma and COPD inhaler devices including controller and reliever metered dose inhalers (MDIs), and other inhaler devices (dry powder inhalers (DPIs) and soft mist inhalers (SMIs)).
GSK has been a leader in respiratory for over 45 years, developing new and first-in-class medicines, approaches and insights which have helped to influence and support the management of asthma and chronic obstructive pulmonary disease (COPD). The ELLIPTA inhaler is a platform inhaler device that is being used by GSK in the development of a range of innovative medicines across its clinical development portfolio for respiratory diseases.
Propeller empowers people with asthma and COPD to live measurably better lives. In 2010 Propeller set out to modernize respiratory medicine, enable people to minimize the impact of asthma and COPD on their daily lives, and connect them to their physicians, environment and community. Propeller’s information-powered approach to respiratory management guides physicians and patients to the optimal path of therapy for each individual. With connected inhalers, digital interfaces, and personalized insights, participants receive personal guidance and expert direction anytime. Backed by 3M Ventures (NYSE: MMM), SR One, Hikma Ventures (LON: HIK), Safeguard Scientifics (NYSE: SFE), Social Capital and other investors, Propeller received the American Telemedicine Association’s 2016 President’s Award for Innovation in Remote Healthcare and was recognized as one of the top “Fierce 15” medical device companies in 2015 by FierceMedicalDevices. In 2017, Fast Company named Propeller as one of the most innovative companies in Health. For more information visit: www.propellerhealth.com